Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases
Objective: To describe the visual and clinical outcomes of 3 patients with sympathetic ophthalmia treated with a combination of systemic steroids and methotrexate. Methods: This was a small, descriptive case series. Results: We reported 3 cases of post-traumatic sympathetic ophthalmia treate...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Philippine Academy of Ophthalmology
2020-06-01
|
| Series: | Philippine Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://paojournal.com/index.php/pjo/article/view/91 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850226324279394304 |
|---|---|
| author | Corrina P. Azarcon, MD Franz Marie Cruz, MD Teresita R. Castillo, MD Cheryl A. Arcinue, MD |
| author_facet | Corrina P. Azarcon, MD Franz Marie Cruz, MD Teresita R. Castillo, MD Cheryl A. Arcinue, MD |
| author_sort | Corrina P. Azarcon, MD |
| collection | DOAJ |
| description | Objective: To describe the visual and clinical outcomes of 3 patients with sympathetic ophthalmia treated with a combination of systemic steroids and methotrexate.
Methods: This was a small, descriptive case series.
Results: We reported 3 cases of post-traumatic sympathetic ophthalmia treated with steroids and methotrexate. Two patients had inciting eyes with no light perception on presentation, while one had a best-corrected visual acuity (BCVA) of counting fingers. The initial BCVA of the sympathizing eyes ranged from 20/20 to 20/50. Control of ocular inflammation was achieved using methotrexate (12.5 to 15 mg weekly) in addition to oral steroids and topical therapy. The final BCVA of the sympathizing eyes ranged from 20/20 to 20/30, indicating that good visual outcomes were attainable with steroids and methotrexate as part of the maintenance regimen. None of the patients developed adverse side-effects from methotrexate.
Conclusion: This small case series demonstrated the effectiveness and safety of methotrexate for control of intraocular inflammation in sympathetic ophthalmia. |
| format | Article |
| id | doaj-art-6d348c0dea4043f69be75c6eeb99d755 |
| institution | OA Journals |
| issn | 0031-7659 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Philippine Academy of Ophthalmology |
| record_format | Article |
| series | Philippine Journal of Ophthalmology |
| spelling | doaj-art-6d348c0dea4043f69be75c6eeb99d7552025-08-20T02:05:07ZengPhilippine Academy of OphthalmologyPhilippine Journal of Ophthalmology0031-76592020-06-01451485291Methotrexate for Sympathetic Ophthalmia A Report of 3 CasesCorrina P. Azarcon, MD0Franz Marie Cruz, MD1Teresita R. Castillo, MD2Cheryl A. Arcinue, MD3University of the Philippines- Philippine General Hospital, ManilaUniversity of the Philippines- Philippine General Hospital, Manila; Peregrine Eye and Laser Institute, Makati City; St. Luke’s Medical Center, Quezon CityUniversity of the Philippines- Philippine General Hospital, ManilaUniversity of the Philippines- Philippine General Hospital, Manila; Asian Eye Institute, Makati CityObjective: To describe the visual and clinical outcomes of 3 patients with sympathetic ophthalmia treated with a combination of systemic steroids and methotrexate. Methods: This was a small, descriptive case series. Results: We reported 3 cases of post-traumatic sympathetic ophthalmia treated with steroids and methotrexate. Two patients had inciting eyes with no light perception on presentation, while one had a best-corrected visual acuity (BCVA) of counting fingers. The initial BCVA of the sympathizing eyes ranged from 20/20 to 20/50. Control of ocular inflammation was achieved using methotrexate (12.5 to 15 mg weekly) in addition to oral steroids and topical therapy. The final BCVA of the sympathizing eyes ranged from 20/20 to 20/30, indicating that good visual outcomes were attainable with steroids and methotrexate as part of the maintenance regimen. None of the patients developed adverse side-effects from methotrexate. Conclusion: This small case series demonstrated the effectiveness and safety of methotrexate for control of intraocular inflammation in sympathetic ophthalmia.https://paojournal.com/index.php/pjo/article/view/91sympathetic ophthalmiasteroidsmethotrexateclinical outcomespanuveitis |
| spellingShingle | Corrina P. Azarcon, MD Franz Marie Cruz, MD Teresita R. Castillo, MD Cheryl A. Arcinue, MD Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases Philippine Journal of Ophthalmology sympathetic ophthalmia steroids methotrexate clinical outcomes panuveitis |
| title | Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases |
| title_full | Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases |
| title_fullStr | Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases |
| title_full_unstemmed | Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases |
| title_short | Methotrexate for Sympathetic Ophthalmia A Report of 3 Cases |
| title_sort | methotrexate for sympathetic ophthalmia a report of 3 cases |
| topic | sympathetic ophthalmia steroids methotrexate clinical outcomes panuveitis |
| url | https://paojournal.com/index.php/pjo/article/view/91 |
| work_keys_str_mv | AT corrinapazarconmd methotrexateforsympatheticophthalmiaareportof3cases AT franzmariecruzmd methotrexateforsympatheticophthalmiaareportof3cases AT teresitarcastillomd methotrexateforsympatheticophthalmiaareportof3cases AT cherylaarcinuemd methotrexateforsympatheticophthalmiaareportof3cases |